Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress - The ASPIRE-AF Trial
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress - The ASPIRE-AF Trial
Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring transiently with stress and additional stroke risk factors.
ASPIRE-AF is a prospective, randomized, open-label trial of non-vitamin K oral anticoagulants (NOACs) versus no oral anticoagulation in patients with transient atrial fibrillation and additional stroke factors occurring transiently with stress. The primary objective is to assess the effects of NOACs versus no anticoagulation on the co-primary composite outcomes of 1. non-hemorrhagic stroke and systemic embolism, and 2. vascular mortality, and non-fatal non-hemorrhagic stroke, myocardial infarction, peripheral arterial thrombosis, amputation, and symptomatic venous thromboembolism over the duration of follow-up.
Inclusion Criteria:
have ≥1 episode of clinically important AFOTS during any of the following conditions:
sinus rhythm at the time of randomization;
any of the following high-risk criteria:
provide written informed consent
Exclusion Criteria:
aspireaf@phri.ca1-905-594-0560
Los Angeles, California 90048, United States
San Miguel de Tucumán, Tucumán Province 4000, Argentina
Moncton, New Brunswick E1C 2Z3, Canada
Sherbrooke, Quebec J1H 5H3, Canada
Esbjerg, 6700, Denmark
Alessandria, 15121, Italy